CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF554 (ImmuneEditome ID:115196)

1. Gene summary of enriched editing regions for ZNF554

check button Gene summary
Gene informationGene symbol

ZNF554

Gene ID

115196

GeneSynonyms-
GeneCytomap

19p13.3

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 554
GeneModificationdate20230518
UniprotIDQ86TJ5;K7EQV8;K7EIR8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:2835035-2835619:+ENST00000588534.1ENSG00000172006.10ZNF554ncRNA_exonicAluJr,AluYchr19:2835035-2835619:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF554


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:2835035-2835619:+BRCAEER3.3837e-02image
ENSG00000172006.10,ZNF554BRCAEAG3.3857e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF554


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for ZNF554


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000172006.10,ZNF554
THYMEAGIRENSG00000100813.10chr1423068362:23069617:23071124:230711860.29854.3980e-023.6147e-040.4037imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184ACIN1T_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
ENSG00000172006.10,ZNF554
THYMEAGMEXENSG00000129657.10chr1777213917:77215753:77215792:77215948:77216010:77216075:77216127:772161400.27644.1057e-025.1151e-040.4047imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000172006.10,ZNF554
THYMEAGIRENSG00000100207.14chr2242168608:42168736:42169846:421698960.38604.5387e-032.7260e-050.4383imageNADAR;AIFM1;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;METTL3;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAPlasma_cellsGSVA_HALLMARK_P53_PATHWAY
ENSG00000172006.10,ZNF554
THYMEAGIRENSG00000242485.1chr11405108:1405886:1406225:14063070.35188.8025e-031.0534e-040.4383imageNADAR;AIFM1;AUH;BUD13;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMast_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000172006.10,ZNF554
THYMEAGESENSG00000105127.4chr1915368234:15368322:15369066:15369224:15370145:153701790.38808.4931e-034.7224e-050.4218imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NANK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000172006.10,ZNF554
THYMEAGMEXENSG00000129657.10chr1777213917:77215753:77215792:77215971:77216010:77216075:77216127:772161400.30202.1265e-022.1235e-040.4205imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000172006.10,ZNF554
THYMEAGIRENSG00000164808.12chr847728932:47729102:47729411:477294650.32822.4321e-026.8864e-060.4820imageNADAR;AIFM1;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28A;LIN28B;LSM11;METTL3;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SND1;SRSF1;SRSF3;SRSF9;TAF15;U2AF2;UPF1;YTHDF1;ZNF184NANK_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000172006.10,ZNF554
THYMEAGIRENSG00000185658.9chr2139296264:39296363:39298431:39298582-0.35461.3722e-021.4998e-05-0.4261imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;ZNF184NANK_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000172006.10,ZNF554
THYMEAGMEXENSG00000129657.10chr1777213917:77215753:77215792:77215818:77215818:77216075:77216127:772161400.30911.6581e-021.1756e-040.4412imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000172006.10,ZNF554
THYMEAGMEXENSG00000129657.10chr1777213917:77215753:77215792:77215818:77215831:77216075:77216127:772161400.27504.1245e-025.2301e-040.4040imageNADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF9;TAF15;TIA1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for ZNF554


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000172006.10,ZNF554ACCEAGMast_cells_resting5.1844e-030.4896image
chr19:2835035-2835619:+BRCAEERT_cells_CD4_memory_resting4.3342e-040.1335image
ENSG00000172006.10,ZNF554BRCAEAGT_cells_CD4_memory_resting4.4389e-040.1333image
chr19:2835035-2835619:+CESCEEREosinophils4.3989e-02-0.1730image
ENSG00000172006.10,ZNF554CESCEAGEosinophils4.3989e-02-0.1730image
chr19:2835035-2835619:+ESCAEERB_cells_memory2.7501e-020.3058image
ENSG00000172006.10,ZNF554ESCAEAGB_cells_memory2.6295e-020.3081image
ENSG00000172006.10,ZNF554HNSCEAGNK_cells_resting4.1256e-02-0.2643image
ENSG00000172006.10,ZNF554KICHEAGEosinophils1.4843e-050.5917image
chr19:2835035-2835619:+LUADEERT_cells_gamma_delta7.8948e-040.3287image
ENSG00000172006.10,ZNF554LUADEAGT_cells_gamma_delta7.8933e-040.3287image
chr19:2835035-2835619:+LUSCEERT_cells_CD81.0639e-03-0.2905image
ENSG00000172006.10,ZNF554LUSCEAGT_cells_CD81.0639e-03-0.2905image
chr19:2835035-2835619:+OVEERPlasma_cells1.1518e-030.3860image
ENSG00000172006.10,ZNF554OVEAGPlasma_cells9.7238e-040.3912image
ENSG00000172006.10,ZNF554PAADEAGT_cells_CD4_memory_activated3.6984e-02-0.3085image
chr19:2835035-2835619:+PCPGEERT_cells_CD4_memory_resting5.4167e-030.2709image
ENSG00000172006.10,ZNF554PCPGEAGT_cells_CD4_memory_resting5.4167e-030.2709image
chr19:2835035-2835619:+SKCMEERT_cells_follicular_helper6.0408e-03-0.2701image
ENSG00000172006.10,ZNF554SKCMEAGT_cells_follicular_helper6.0408e-03-0.2701image
chr19:2835035-2835619:+STADEERT_cells_follicular_helper3.2862e-030.3268image
ENSG00000172006.10,ZNF554STADEAGT_cells_follicular_helper3.3006e-030.3152image
ENSG00000172006.10,ZNF554THYMEAGNK_cells_activated3.0421e-020.2188image
ENSG00000172006.10,ZNF554UCSEAGDendritic_cells_activated6.4417e-030.5111image
ENSG00000172006.10,ZNF554UVMEAGPlasma_cells3.0836e-030.5894image


Top

6. Enriched editing regions and immune gene sets for ZNF554


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000172006.10,ZNF554ACCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG3.6727e-020.3767image
ENSG00000172006.10,ZNF554BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.8021e-020.1935image
chr19:2835035-2835619:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.8021e-020.1935image
ENSG00000172006.10,ZNF554BRCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG6.5687e-060.1705image
chr19:2835035-2835619:+BRCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER6.5066e-060.1706image
ENSG00000172006.10,ZNF554COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3076e-020.4553image
ENSG00000172006.10,ZNF554ESCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.6502e-020.3311image
chr19:2835035-2835619:+ESCAGSVA_HALLMARK_NOTCH_SIGNALINGEER1.5721e-020.3334image
ENSG00000172006.10,ZNF554GBMGSVA_HALLMARK_HEME_METABOLISMEAG3.6136e-020.1847image
chr19:2835035-2835619:+GBMGSVA_HALLMARK_HEME_METABOLISMEER3.6136e-020.1847image
chr19:2835035-2835619:+LGGGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.6584e-030.1538image
ENSG00000172006.10,ZNF554LGGGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.6441e-030.1539image
chr19:2835035-2835619:+LIHCGSVA_HALLMARK_G2M_CHECKPOINTEER1.8979e-030.2752image
ENSG00000172006.10,ZNF554LIHCGSVA_HALLMARK_G2M_CHECKPOINTEAG1.8979e-030.2752image
chr19:2835035-2835619:+LUADGSVA_HALLMARK_PEROXISOMEEER2.3823e-03-0.2991image
ENSG00000172006.10,ZNF554LUADGSVA_HALLMARK_PEROXISOMEEAG2.3996e-03-0.2988image
ENSG00000172006.10,ZNF554LUSCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.4232e-020.1903image
chr19:2835035-2835619:+LUSCGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.4232e-020.1903image
ENSG00000172006.10,ZNF554MESOGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.9655e-02-0.3678image
chr19:2835035-2835619:+OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.2417e-02-0.2598image
ENSG00000172006.10,ZNF554OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG4.7201e-02-0.2416image
ENSG00000172006.10,ZNF554PAADGSVA_HALLMARK_PEROXISOMEEAG2.5982e-020.3282image
chr19:2835035-2835619:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.8055e-030.3024image
ENSG00000172006.10,ZNF554PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.8055e-030.3024image
ENSG00000172006.10,ZNF554SARCGSVA_HALLMARK_PEROXISOMEEAG2.7132e-040.3362image
chr19:2835035-2835619:+SARCGSVA_HALLMARK_PEROXISOMEEER2.6031e-040.3372image
chr19:2835035-2835619:+SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.7497e-030.3062image
ENSG00000172006.10,ZNF554SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.7497e-030.3062image
chr19:2835035-2835619:+STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.2194e-020.2808image
ENSG00000172006.10,ZNF554STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.1500e-020.2729image
ENSG00000172006.10,ZNF554TGCTGSVA_HALLMARK_UV_RESPONSE_DNEAG3.6101e-020.2088image
chr19:2835035-2835619:+TGCTGSVA_HALLMARK_UV_RESPONSE_DNEER3.6101e-020.2088image
ENSG00000172006.10,ZNF554THCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.7720e-020.1014image
chr19:2835035-2835619:+THCAGSVA_HALLMARK_MITOTIC_SPINDLEEER4.7720e-020.1014image
ENSG00000172006.10,ZNF554THYMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG7.8522e-04-0.3337image
ENSG00000172006.10,ZNF554UCECGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG5.6042e-030.3109image
ENSG00000172006.10,ZNF554UCSGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG7.0854e-030.5060image


Top

7. Enriched editing regions and drugs for ZNF554


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000172006.10,ZNF554ACCJW.7.52.1EAG1.9925e-02-0.4160image
ENSG00000172006.10,ZNF554BLCAAZD6482EAG2.3230e-02-0.1998image
chr19:2835035-2835619:+BLCAAZD6482EER2.3230e-02-0.1998image
chr19:2835035-2835619:+BRCACHIR.99021EER1.8694e-07-0.1968image
ENSG00000172006.10,ZNF554BRCACHIR.99021EAG1.9438e-07-0.1966image
ENSG00000172006.10,ZNF554CESCGDC0941EAG3.0185e-02-0.1860image
chr19:2835035-2835619:+CESCGDC0941EER3.0185e-02-0.1860image
ENSG00000172006.10,ZNF554COADCI.1040EAG1.5064e-02-0.4470image
ENSG00000172006.10,ZNF554HNSCCMKEAG1.3885e-020.3161image
ENSG00000172006.10,ZNF554KICHBI.2536EAG4.6565e-02-0.2950image
ENSG00000172006.10,ZNF554KIRCCytarabineEAG3.9191e-02-0.1658image
ENSG00000172006.10,ZNF554KIRPA.770041EAG3.2364e-020.2198image
chr19:2835035-2835619:+KIRPA.770041EER3.2364e-020.2198image
chr19:2835035-2835619:+LGGGefitinibEER5.6146e-040.1684image
ENSG00000172006.10,ZNF554LGGGefitinibEAG5.6332e-040.1684image
ENSG00000172006.10,ZNF554LIHCJNK.Inhibitor.VIIIEAG1.1185e-03-0.2882image
chr19:2835035-2835619:+LIHCJNK.Inhibitor.VIIIEER1.1185e-03-0.2882image
ENSG00000172006.10,ZNF554LUADDocetaxelEAG5.7446e-03-0.2730image
chr19:2835035-2835619:+LUADDocetaxelEER5.7139e-03-0.2732image
ENSG00000172006.10,ZNF554LUSCLapatinibEAG8.4806e-03-0.2354image
chr19:2835035-2835619:+LUSCLapatinibEER8.4806e-03-0.2354image
ENSG00000172006.10,ZNF554MESOCI.1040EAG1.8206e-02-0.4355image
chr19:2835035-2835619:+OVErlotinibEER1.3093e-020.2995image
ENSG00000172006.10,ZNF554OVAICAREAG1.8344e-02-0.2853image
ENSG00000172006.10,ZNF554PCPGCamptothecinEAG2.0592e-030.2988image
chr19:2835035-2835619:+PCPGCamptothecinEER2.0592e-030.2988image
ENSG00000172006.10,ZNF554SARCATRAEAG1.5239e-03-0.2948image
chr19:2835035-2835619:+SARCATRAEER1.4275e-03-0.2965image
ENSG00000172006.10,ZNF554SKCMBosutinibEAG1.6846e-020.2362image
chr19:2835035-2835619:+SKCMBosutinibEER1.6846e-020.2362image
chr19:2835035-2835619:+STADCCT018159EER2.5890e-03-0.3345image
ENSG00000172006.10,ZNF554STADCCT018159EAG3.8564e-03-0.3103image
ENSG00000172006.10,ZNF554TGCTJNJ.26854165EAG6.2498e-030.2704image
chr19:2835035-2835619:+TGCTJNJ.26854165EER6.2498e-030.2704image
ENSG00000172006.10,ZNF554THCAJNK.Inhibitor.VIIIEAG6.1505e-04-0.1745image
chr19:2835035-2835619:+THCAJNK.Inhibitor.VIIIEER6.1505e-04-0.1745image
ENSG00000172006.10,ZNF554THYMBortezomibEAG2.2891e-030.3046image
ENSG00000172006.10,ZNF554UCSCCT018159EAG3.6546e-020.4042image
ENSG00000172006.10,ZNF554UVMMetforminEAG4.7026e-020.4182image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType